NCT00828750

Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)-An Extension Study of Eltrombopag in Subjects, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study TRA108109 (NCT00540423)-<Phase III Study>

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

An open-label, dose-adjustment extension study to evaluate the safety and efficacy of eltrombopag for treatment of subjects with ITP who have previously been enrolled in the eltrombopag trial TRA108109 (NCT00540423).

Conditions

• Idiopathic Thrombocytopenic Purpura
• Purpura, Thrombocytopenic, Idiopathic

Interventions

Type	Name	Description
DRUG	Eltrombopag oral tablets	Eltrombopag oral tablets once daily

Timeline

• Start date: 2008-05-01
• Primary completion: 2011-02-01
• Completion: 2011-02-01
• First posted: 2009-01-26
• Last updated: 2018-09-17
• Results posted: 2011-12-01

Locations

6 sites across 1 country: Japan